Neuroblastoma and bone metastases: Clinical significance and prognostic value of Dickkopf 1 plasma levels

Bone

Volumn 48, Issue 1, 2011, Pages 152-159

  Granchi, Donatella ^a   Corrias, Maria Valeria ^b   Garaventa, Alberto ^b   Baglìo, Serena Rubina ^a   Cangemi, Giuliana ^b   Carlini, Barbara ^b   Paolucci, Paolo ^c   Giunti, Armando ^a   Baldini, Nicola ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Bone metastasis; Dickkopf 1; Neuroblastoma; Osteoblast; Wnt pathway

Indexed keywords

DICKKOPF 1 PROTEIN; DOXORUBICIN; SMALL INTERFERING RNA;

ADOLESCENT; ARTICLE; BONE METASTASIS; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HOSPITALIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRESCHOOL CHILD; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD;

ADULT; BONE AND BONES; BONE MARROW NEOPLASMS; BONE NEOPLASMS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CHILD; COHORT STUDIES; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEUROBLASTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 78650310298     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.06.028     Document Type: Article

References (50)

1. Clines G.A., Guise T.A. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008, 10:e7.
2. Park J.R., Eggert A., Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am 2008, 55:97-120.
3. Brodeur G.M., Pritchard J., Berthold F., Carlsen N.L., Castel V., Castelberry R.P., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993, 11:1466-1477.
4. Weinstein J.L., Katzenstein H.M., Cohn S.L. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003, 8:278-292.
5. Ladenstein R., Philip T., Lasset C., Hartmann O., Garaventa A., Pinkerton R., et al. Multivariate analysis of risk factors in Stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998, 16:953-965.
6. Fish J.D., Grupp S.A. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 2008, 41:159-165.
7. Michigami T., Ihara-Watanabe M., Yamazaki M., Ozono K. Receptor activator of nuclear factor kB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001, 61:1637-1644.
8. Granchi D., Amato I., Battistelli L., Avnet S., Capaccioli S., Papucci L., et al. In vitro blockade of receptor activator of nuclear factor-kB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int J Cancer 2004, 111:829-838.
9. Sohara Y., Shimada H., Minkin C., Erdreich-Epstein A., Nolta J.A., DeClerck Y.A. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res 2005, 65:1129-1135.
10. Sohara Y., Shimada H., DeClerck Y.A. Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Lett 2005, 228:203-209.
11. Ara T., DeClerck Y.A. Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Rev 2006, 25:645-657.
12. Granchi D., Garaventa A., Amato I., Paolucci P., Baldini N. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma. Int J Cancer 2006, 119:146-151.
13. Ara T., Song L., Shimada H., Keshelava N., Russell H.V., Metelitsa L.S., et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009, 69:329-337.
14. Granchi D., Baglìo S.R., Amato I., Giunti A., Baldini N. Paracrine inhibition of osteoblast differentiation induced by neuroblastoma cells. Int J Cancer 2008, 123:1526-1535.
15. Chen Y., Alman B.A. Wnt pathway, an essential role in bone regeneration. J Cell Biochem 2009, 106:353-362.
16. Gregory C.A., Gunn W.G., Reyes E., Smolarz A.J., Munoz J., Spees J.L., et al. How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann NY Acad Sci 2005, 1049:97-106.
17. Bodine P.V., Komm B.S. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 2006, 7:33-39.
18. Qiang Y.W., Barlogie B., Rudikoff S., Shaughnessy J.D. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 2008, 42:669-680.
19. Voorzanger-Rousselot N., Goehrig D., Journe F., Doriath V., Body J.J., Clézardin P., et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007, 97:964-970.
20. Hall C.L., Bafico A., Dai J., Aaronson S.A., Keller E.T. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005, 65:7554-7560.
21. Pinzone J.J., Hall B.M., Thudi N.K., Vonau M., Qiang Y.W., Rosol T.J., et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 113:517-525.
22. Kaiser M., Mieth M., Liebisch P., Oberländer R., Rademacher J., Jakob C., et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008, 80:490-494.
23. Voorzanger-Rousselot N., Journe F., Doriath V., Body J.J., Garnero P. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases. Calcif Tissue Int 2009, 84:348-354.
24. Le Sheng S., Huang G., Yu B., Qin W.X. Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem 2009, 55:1656-1664.
25. Voskaridou E., Christoulas D., Xirakia C., Varvagiannis K., Boutsikas G., Bilalis A., et al. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 2009, 94:725-728.
26. Marshall M.J., Evans S.F., Sharp C.A., Powell D.E., McCarthy H.S., Davie M.W. Increased circulating Dickkopf-1 in Paget's disease of bone. Clin Biochem 2009, 42:965-969.
27. Ueland T., Otterdal K., Lekva T., Halvorsen B., Gabrielsen A., Sandberg W.J., et al. Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:1228-1234.
28. Jiang T., Wang S., Huang L., Zhang S. Clinical significance of serum DKK-1 in patients with gynecological cancer. Int J Gynecol Cancer 2009, 19:1177-1181.
29. De Bernardi B., Conte M., Mancini A., Donfrancesco A., Alvisi P., Tomà P., et al. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 1995, 13:884-893.
30. Garaventa A., Boni L., Lo Piccolo M.S., Tonini G.P., Gambini C., Mancini A., et al. Italian Cooperative Group for Neuroblastoma: localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol 2002, 13:956-964.
31. De Bernardi B., Nicolas B., Boni L., Indolfi P., Carli M., Cordero Di Montezemolo L., et al. Italian co-operative group for neuroblastoma: disseminated neuroblastoma in children older than one year at diagnosis: Comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003, 21:1592-1601.
32. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B. Terminology and morphologic criteria of neuroblastic tumors. Cancer 1999, 86:349-363.
33. Altungoz O., Aygun N., Tumer S., Ozer E., Olgun N., Sakizli M. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma. Cancer Genet Cytogenet 2007, 172:113-119.
34. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. Standards for reporting of diagnostic accuracy steering group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003, 326:41-44.
35. Deeks J.J. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001, 323:157-162.
36. Wang J., Shou J., Chen X. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene 2000, 19:1843-1848.
37. Mikheev A.M., Mikheeva S.A., Liu B., Cohen P., Zarbl H. A functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation. Carcinogenesis 2004, 25:47-59.
38. Forget M.A., Turcotte S., Beauseigle D., Godin-Ethier J., Pelletier S., Martin J., et al. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumors and in some common cancer types. Br J Cancer 2007, 96:646-653.
39. Yamabuki T., Takano A., Hayama S., Ishikawa N., Kato T., Miyamoto M., et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007, 67:2517-2525.
40. Voorzanger-Rousselot N., Goehrig D., Facon T., Clézardin P., Garnero P. Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol 2009, 145:264-266.
41. Koppen A., Ait-Aissa R., Hopman S., Koster J., Haneveld F., Versteeg R., et al. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. Cancer Lett 2007, 256:218-228.
42. Liu X., Mazanek P., Dam V., Wang Q., Zhao H., Guo R., et al. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 2008, 27:1478-1488.
43. Flahaut M., Meier R., Coulon A., Nardou K.A., Niggli F.K., Martinet D., et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 2009, 28:2245-2256.
44. Thiago L.S., Costa E.S., Lopes D.V., Otazu I.B., Nowill A.E., Mendes F.A., et al. The Wnt signaling pathway regulates Nalm-16 B-cell precursor acute lymphoblastic leukemic cell line survival and etoposide resistance. Biomed Pharmacother 2010, 64:63-72.
45. Selga E., Oleaga C., Ramírez S., de Almagro M.C., Noé V., Ciudad C.J. Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome Med 2009, 1:83.1-83.16.
46. Blaney S.M., Bernstein M., Neville K., Ginsberg J., Kitchen B., Horton T., et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 2004, 22:4804-4809.
47. Michaelis M., Fichtner I., Behrens D., Haider W., Rothweiler F., Mack A., et al. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 2006, 28:439-446.
48. Brignole C., Marimpietri D., Pastorino F., Nico B., Di Paolo D., Cioni M., et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006, 98:1142-1157.
49. Hamner J.B., Dickson P.V., Sims T.L., Zhou J., Spence Y., Ng C.Y., et al. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery 2007, 142:185-191.
50. A study to assess BHQ880 in combination with zoledronic acid in relapsed or refractory myeloma patients. August, 2008. http://clinicaltrials.gov/ct2/show/NCT00741377.